
CAS 1130067-06-9
:Formula:C26H28Cl2N4O2
InChI:InChI=1S/C26H27ClN4O2.ClH/c1-17(28-25(32)20-7-6-18-4-2-3-5-19(18)14-20)16-30-12-10-22(11-13-30)31-24-9-8-21(27)15-23(24)29-26(31)33;/h2-9,14-15,17,22H,10-13,16H2,1H3,(H,28,32)(H,29,33);1H/t17-;/m0./s1
InChI key:RQULTQQAHGYYDG-LMOVPXPDSA-N
SMILES:C[C@@H](CN1CCC(CC1)N2C3=C(C=C(C=C3)Cl)NC2=O)NC(=O)C4=CC5=CC=CC=C5C=C4.Cl
Filtra per
Percentuale di purezza
0
100
|
0
|
50
|
90
|
95
|
100
Trovati 6 prodotti.
- Prezzo più basso
- Prezzo più alto
- Purezza più bassa
- Purezza più alta
- Consegna più veloce
VU-0155069
CAS:VU-0155069Formula:C26H27ClN4O2Purezza:98%Colore e forma:SolidPeso molecolare:462.97117(S)-N-(1-(4-(5-Chloro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-naphthamide
CAS:Formula:C26H27ClN4O2Purezza:≥98%Peso molecolare:462.98VU-0155069
CAS:VU-0155069 is a small molecule that inhibits fatty acid uptake and metabolism in the kidney. It has been shown to suppress tumor growth in a mouse model of breast cancer by inhibiting fatty acid uptake and metabolism, which reduces the production of proinflammatory molecules. VU-0155069 also inhibits the cation channel CLCN2 in glioma patients, which leads to reduced tumor growth. This drug has shown efficacy in human clinical trials for patients with chronic kidney disease who have not responded to other therapies. VU-0155069 is being investigated as an adjuvant treatment for glioma patients who have already undergone surgery or radiation therapy. VU-0155069 can be used to treat neurodegenerative diseases such as Parkinson's disease by restoring synaptic dysfunction and reducing inflammation.Formula:C26H27ClN4O2Purezza:Min. 95%Peso molecolare:462.97 g/molVU0155069
CAS:VU0155069, a selective PLD1 inhibitor (IC50: 46 nM), halts cancer cell migration in transwell assays.Formula:C26H27ClN4O2Purezza:99.5%Colore e forma:White SolidPeso molecolare:462.97





